On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVIDﾙ for treating illness caused by combined infections with influenza and COVID-19.

FLUVID therapy will combine XBiotechﾒs breakthrough influenza True Human antibodies together with its recently discovered COVID-19 antibodies into one treatment.